By employing artificial intelligence-assisteddrug design, thegroup led by Lei Li developed Se-AR PROTAC, a peptide-baseddegrader capable of degrading AR by forming a ternary complex withthe von Hippel–Lindau (VHL) E3 ligase, with a DC50 of 693 nM in AR-positive prostate cancer cells (Figure ). Here, AR is linked to prostate carcinoma.